Kenji Kawashima

This inventor holds 19 USPTO granted patents, plus 1 CIPO patent and 10 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Santen Pharmaceutical Co., Ltd., Ayumi Pharmaceutical Corporation. Active years: 2009-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kenji Kawashima. Retrieved from https://idiyas.com/inventor/kenji-kawashima

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 19

% Patents Active = 15.8

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 10 (Patent Applications = 2)

Average Co-Inventor Count = 6.5

ph-index = 3

Forward Citations = 30(Granted Patents)

Location History:

Osaka, JP (2019)
Ikoma, JP (2009 - 2021)

Company Filing History:

18 out of 282

Santen Pharmaceutical Co., Ltd.

patents

1 out of 3

Ayumi Pharmaceutical Corporation

patents

Years Active: 2009-2021

Loading Chart...

Areas of Expertise:

Glucocorticoid Receptor Binding

PARP Inhibitors

Indole Derivatives

Cyclic Compounds

Quinoxaline Compounds

Pyrrole Derivatives

4-Pyridylalkylthio Group

Aminocarbonyl Group

Ureido Group

Substituted Compounds

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11186588 - 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative (2021-11-30),

2. 10435379 - [4-(1,3,3-trimethyl-2-OXO-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or salt thereof (2019-10-08),

3. 10189796 - [4-(1,3,3-trimethyl-2-oxo-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or salt thereof (2019-01-29),

4. 9062061 - Compound having PARP inhibitory activity (2015-06-23),

5. 8975256 - 1,2,3,4-tetrahydroquinoxaline compounds having glucocorticoid receptor binding activity (2015-03-10),

6. 8551991 - 1,2,3,4-tetrahydroquinoxaline derivative having glucocorticoid receptor binding activity (2013-10-08),

7. 8518973 - Compounds having 4-pyridylalkylthio group as a substituent (2013-08-27),

8. 8507485 - Cyclic compound having pyrimidinylalkylthio group (2013-08-13),

9. 8445529 - Indole derivative having, carbamoyl group, ureido group and substituted oxy group (2013-05-21),

10. 8420635 - Method for preventing or treating a glucocorticoid receptor-related disease (2013-04-16),

11. 8207194 - Compounds having a 4-pyridylalkylthio group as a substituent (2012-06-26),

12. 8193237 - Indole derivative having IκB kinase β inhibitory activity (2012-06-05),

13. 8088817 - Pyrrole derivative having, as substituents, ureido group, aminocarbonly group and bicyclic group which may have substituent (2012-01-03),

14. 8017775 - 1-2-dihydroquinoline derivative having glucocorticoid receptor binding activity (2011-09-13),

15. 7977371 - Pyrrole derivative having ureido group and aminocarbonyl group as substituents (2011-07-12),

Title: Kenji Kawashima: Innovator in Pharmaceutical Patents

Introduction

Kenji Kawashima, based in Ikoma, Japan, is an accomplished inventor with a remarkable portfolio of 19 patents. His innovative contributions primarily revolve around pharmaceutical compounds, showcasing his significant impact in the field of medicinal chemistry.

Latest Patents

Among his latest inventions, Kawashima developed a compound known as 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative. This compound exhibits BRD4 inhibitory activity, positioning it as a potential therapeutic agent for diseases associated with BRD4. Another notable patent includes the development of a [4-(1,3,3-trimethyl-2-OXO-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or its salts. This innovation holds glucocorticoid receptor agonist activity, making it a valuable candidate for treating glucocorticoid receptor-related diseases.

Career Highlights

Kawashima has made significant strides in the pharmaceutical industry, having worked with esteemed companies such as Santen Pharmaceutical Co., Ltd. and Ayumi Pharmaceutical Corporation. His contributions within these organizations have been instrumental in advancing medicinal research and drug development.

Collaborations

Throughout his career, Kawashima has collaborated with other notable figures such as Minoru Yamamoto and Takahiro Honda. These partnerships highlight the collaborative nature of innovation in the pharmaceutical sector, where sharing knowledge and expertise can lead to groundbreaking advancements.

Conclusion

Kenji Kawashima’s innovative spirit and dedication to research have positioned him as a leading inventor in the pharmaceutical field. With a strong portfolio of patents and significant collaborations, he continues to contribute to the advancement of medicinal science, demonstrating the essential role of inventors in improving healthcare.

Profile summary based on public USPTO records.